Skip NavigationSkip to Content
Return Return to Search Results

A Novel Anionic-phosphate-platinum Complex Effectively Targets a Cisplatinum-resistant Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model

  1. Author:
    Igarashi, Kentaro
    Kawaguchi, Kei
    Yamamoto, Norio
    Hayashi, Katsuhiro
    Kimura, Hiroaki
    Miwa, Shinji
    Higuchi, Takashi
    Taniguchi, Yuta
    Yonezawa, Hirotaka
    Araki, Yoshihiro
    Morinaga, Sei
    Misra,Sweta
    Nelson, Scott D.
    Dry, Sarah M.
    Li, Yunfeng
    Odani, Akira
    Singh,Shree Ram
    Tsuchiya, Hiroyuki
    Hoffman, Robert M.

  2. Author Address

    AntiCanc Inc, 7917 Ostrow St, San Diego, CA 92111 USA.Univ Calif San Diego, Dept Surg, San Diego, CA USA.Kanazawa Univ, Dept Orthopaed Surg, Kanazawa, Ishikawa, Japan.NCI, Mouse Canc Genet Program, Frederick, MD 21701 USA.Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA.Kanazawa Univ, Div Pharmaceut Sci, Kanazawa, Ishikawa, Japan.NCI, Basic Res Lab, Frederick, MD 21701 USA.
    1. Year: 2020
    2. Date: May-Jun
  2. Journal: Cancer genomics & proteomics
  3. INT INST ANTICANCER RESEARCH,
    1. 17
    2. 3
    3. Pages: 217-223
  5. Type of Article: Article
  6. ISSN: 1109-6535
  1. Abstract:

    Background/Aim: We have previously developed a novel bone-targeting platinum compound, 3Pt, and showed that it has strong inhibitory activity against osteosarcoma cells and orthotopic cell-line xenograft mouse models. In the present report, we compared the efficacy of 3Pt to cisplatinum (CDDP) in a CDDP-resistant relapsed osteosarcoma patient-derived orthotopic xenograft (PDOX) mouse model. Patients and Methods: The tumor of a patient with osteosarcoma of the distal femur was treated with CDDP-based chemotherapy followed by surgery. The surgical specimen was used to establish a PDOX model. An osteosarcoma cell line was also established from the original patient tumor. Osteosarcoma cell viability was assessed with the WST-8 assay and the IC50 values were calculated. The PDOX models were randomized into three groups: untreated control, CDDP-treated group, and 3Pt-treated group. Tumor size and body weight were measured twice a week. Results: 3Pt had a strong concentration-dependent cytocidal effect in vitro. The IC50 value of 3Pt was significantly lower than that of CDDP. On day 14 of the treatment, 3Pt caused a significantly greater tumor growth inhibition compared to the untreated control and CDDP-treated mice. Conclusion: 3Pt is a promising clinical candidate for the treatment of recalcitrant osteosarcoma.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.21873/cgp.20182
  3. PMID: 32345663
  4. View record in Web of Science®
  5. WOS: 000530098500001

Library Notes

  1. Fiscal Year: FY2019-2020
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel